Related Experiment Video
Updated: Apr 25, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile
Michael John Aldape1, Dustin Delaney Heeney2, Amy Evelyn Bryant3
1Department of Veterans Affairs Medical Center, 500 W. Fort Street, Boise, ID 83702, USA mike.aldape@va.gov.
Background:
Clostridium difficile infection (CDI) is mediated by potent extracellular toxins and is spread largely via bacterial spores. We and others have shown that some antibiotics stimulate C. difficile toxin production in a strain-specific manner; however, the effects of newer anti-C. difficile antibiotics on this process remain to be investigated.
Methods:
The effects of the protein synthesis inhibitor tigecycline on sporulation and toxin A and toxin B production were compared in historical (strain 9689) and hypervirulent BI/NAP1/027 (strain 5325) isolates of C. difficile in vitro.
Results:
Tigecycline at 1/4× MIC stimulated an increased and earlier toxin A and/or B gene expression in both the historical and the hypervirulent strains, although a commensurate increase in toxin protein production was observed only in the 9689 strain. In fact, in the hypervirulent 5325 strain, toxin production was dramatically suppressed. By comparison, subinhibitory concentrations of vancomycin and metronidazole also stimulated increased protein toxin production by the historical, but not the hypervirulent, strain. In addition, tigecycline dose-dependently reduced viable spore production by both the 9689 and 5325 strains. Vancomycin treatment also suppressed spore formation in both C. difficile strains; however, metronidazole, while reducing spore formation in the 9689 strain, stimulated a near 2 log increase in spore production by the 5325 isolate.
Conclusions:
In summary, these findings suggest that the treatment of CDI patients with tigecycline could effectively both control disease progression and limit its spread by disrupting sporulation.
Insights
Tigecycline, an antibiotic, may control Clostridium difficile infection (CDI) by reducing toxin production and inhibiting spore formation in certain strains. This suggests potential for both treating infection and limiting its spread.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Clostridium difficile infection (CDI) is a significant healthcare concern, driven by toxins and spread through spores.
- Existing antibiotics have varied effects on C. difficile toxin production, necessitating investigation of newer agents.
Purpose of the Study:
- To evaluate the impact of tigecycline on C. difficile sporulation and toxin production.
- To compare tigecycline's effects with vancomycin and metronidazole in different C. difficile strains.
Main Methods:
- In vitro comparison of tigecycline's effects on sporulation and toxin A/B production in historical (9689) and hypervirulent (5325) C. difficile strains.
- Assessment of subinhibitory concentrations of vancomycin and metronidazole for comparative analysis.
Main Results:
- Tigecycline increased early toxin gene expression in both strains but only increased toxin protein in the historical strain; it suppressed toxin in the hypervirulent strain.
- Tigecycline dose-dependently reduced viable spore production in both strains.
- Vancomycin suppressed spore formation, while metronidazole had variable effects, stimulating spore production in the hypervirulent strain.
Conclusions:
- Tigecycline demonstrates potential for controlling CDI by disrupting sporulation and modulating toxin production.
- These findings suggest tigecycline could be a valuable therapeutic option for CDI, impacting both disease progression and transmission.
Related Concept Videos
Bacterial Toxins
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Drugs that Destabilize Microtubules
Bacterial Gastroenteritis
Endospores and Sporulation

